Threshold Pharmaceuticals Company Profile (NASDAQ:MTEM)

About Threshold Pharmaceuticals (NASDAQ:MTEM)

Threshold Pharmaceuticals logoMolecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. Evofosfamide is designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not in healthy tissues. Tarloxotinib is under investigation in two Phase II proof-of-concept trials: one for the treatment of patients with mutant EGFR-positive, T790M-negative advanced NSCLC progressing on an EGFR TKI, and the other for patients with recurrent or metastatic squamous cell carcinomas of the head and neck. [18F]-HX4 is an investigational Positron Emission Tomography imaging agent for hypoxia to identify.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MTEM
  • CUSIP: 88580720
  • Web:
  • Market Cap: $173.38 million
  • Outstanding Shares: 26,881,000
Average Prices:
  • 50 Day Moving Avg: $5.63
  • 200 Day Moving Avg: $5.59
  • 52 Week Range: $3.85 - $14.52
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.00
  • P/E Growth: 0.00
  • Return on Equity: -77.61%
  • Return on Assets: -61.41%
  • Current Ratio: 8.41%
  • Quick Ratio: 8.41%
  • Average Volume: 81,570 shs.
  • Beta: 3.24

Frequently Asked Questions for Threshold Pharmaceuticals (NASDAQ:MTEM)

What is Threshold Pharmaceuticals' stock symbol?

Threshold Pharmaceuticals trades on the NASDAQ under the ticker symbol "MTEM."

When did Threshold Pharmaceuticals' stock split? How did Threshold Pharmaceuticals' stock split work?

Threshold Pharmaceuticals shares reverse split before market open on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 1st 2017. An investor that had 100 shares of Threshold Pharmaceuticals stock prior to the reverse split would have 9 shares after the split.

How were Threshold Pharmaceuticals' earnings last quarter?

Threshold Pharmaceuticals, Inc. (NASDAQ:MTEM) released its quarterly earnings results on Monday, July, 31st. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.99. The business had revenue of $3 million for the quarter. View Threshold Pharmaceuticals' Earnings History.

Where is Threshold Pharmaceuticals' stock going? Where will Threshold Pharmaceuticals' stock price be in 2017?

3 brokerages have issued 12-month target prices for Threshold Pharmaceuticals' stock. Their forecasts range from $0.40 to $10.00. On average, they expect Threshold Pharmaceuticals' share price to reach $5.37 in the next twelve months. View Analyst Ratings for Threshold Pharmaceuticals.

Who are some of Threshold Pharmaceuticals' key competitors?

Who are Threshold Pharmaceuticals' key executives?

Threshold Pharmaceuticals' management team includes the folowing people:

  • Harold E. Selick Ph.D., Chairman of the Board
  • Eric E. Poma Ph.D., Chief Executive Officer, Chief Scientific Officer, Director
  • Joel A. Fernandes, Vice President - Finance, Controller
  • Mark Hopkins J.D. Ph.D., Vice President - Intellectual Property and Assistant General Counsel
  • Kristen Quigley, Vice President - Clinical Operations
  • Tillman Pearce M.D., Chief Medical Officer
  • Michael Broxson, Director
  • David Hirsch M.D. Ph.D., Director
  • Kevin M. Lalande, Director
  • Scott Morenstein, Director

How do I buy Threshold Pharmaceuticals stock?

Shares of Threshold Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Threshold Pharmaceuticals' stock price today?

One share of Threshold Pharmaceuticals stock can currently be purchased for approximately $6.24.

MarketBeat Community Rating for Threshold Pharmaceuticals (NASDAQ MTEM)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  192
MarketBeat's community ratings are surveys of what our community members think about Threshold Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Threshold Pharmaceuticals (NASDAQ:MTEM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $5.37 (13.89% downside)

Analysts' Ratings History for Threshold Pharmaceuticals (NASDAQ:MTEM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/3/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$10.00HighView Rating Details
8/3/2017Stifel NicolausReiterated RatingHold$0.40LowView Rating Details
10/3/2016William BlairReiterated RatingOutperformN/AView Rating Details
9/30/2016S&P Equity ResearchLower Price Target$7.37 -> $5.72N/AView Rating Details
12/7/2015Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
12/7/2015Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
10/5/2015Cantor FitzgeraldReiterated RatingBuy$154.00N/AView Rating Details
(Data available from 9/20/2015 forward)


Earnings History for Threshold Pharmaceuticals (NASDAQ:MTEM)
Earnings by Quarter for Threshold Pharmaceuticals (NASDAQ:MTEM)
Earnings History by Quarter for Threshold Pharmaceuticals (NASDAQ MTEM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2017Q2 2017($0.77)$0.22$3.00 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.88)($0.77)ViewN/AView Earnings Details
3/27/2017Q4 2016($0.77)($0.55)ViewN/AView Earnings Details
11/7/2016Q3($0.99)($0.88)ViewN/AView Earnings Details
8/1/2016Q216($1.10)($1.10)ViewN/AView Earnings Details
5/5/2016Q1($0.22)($1.21)ViewN/AView Earnings Details
3/10/2016Q4($1.21)$9.46$4.51 million$65.87 millionViewN/AView Earnings Details
11/2/2015Q315($1.54)($0.99)$3.69 million$3.70 millionViewN/AView Earnings Details
7/30/2015Q2($1.54)($1.32)$3.70 million$3.68 millionViewN/AView Earnings Details
4/30/2015($1.54)($1.87)$3.44 million$3.68 millionViewN/AView Earnings Details
3/3/2015Q414($1.43)($1.32)$4.34 million$3.68 millionViewN/AView Earnings Details
11/3/2014Q314($1.32)($1.65)$3.82 million$3.70 millionViewN/AView Earnings Details
8/1/2014($1.43)($1.32)$4.00 million$3.68 millionViewN/AView Earnings Details
5/1/2014($1.10)($1.32)$9.81 million$3.68 millionViewN/AView Earnings Details
3/6/2014Q413($1.10)($1.43)$3.58 million$3.20 millionViewN/AView Earnings Details
11/4/2013Q313($1.54)$0.22$3.15 million$3.20 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.99)($1.76)$2.80 million$2.90 millionViewN/AView Earnings Details
11/2/2012Q312($0.66)($0.66)$2.29 million$1.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Threshold Pharmaceuticals (NASDAQ:MTEM)
Current Year EPS Consensus Estimate: $-0.74 EPS
Next Year EPS Consensus Estimate: $-0.78 EPS


Dividend History for Threshold Pharmaceuticals (NASDAQ:MTEM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Threshold Pharmaceuticals (NASDAQ:MTEM)
Insider Ownership Percentage: 12.97%
Insider Trades by Quarter for Threshold Pharmaceuticals (NASDAQ:MTEM)
Insider Trades by Quarter for Threshold Pharmaceuticals (NASDAQ:MTEM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/1/2017Jeffrey W BirdDirectorBuy510,703$0.57$291,100.71View SEC Filing  
2/18/2015Wilfred E JaegerDirectorBuy25,000$3.75$93,750.00View SEC Filing  
10/13/2014Nipun DavarVPBuy3,000$2.99$8,970.00View SEC Filing  
10/1/2014Hill Ventures SutterMajor ShareholderSell226,657$3.77$854,496.89View SEC Filing  
10/1/2014Jeffrey W BirdDirectorSell238,520$3.77$899,220.40View SEC Filing  
6/20/2014David L AndersonMajor ShareholderSell13,988$4.01$56,091.88View SEC Filing  
1/16/2014Wilfred JaegerDirectorSell96,356$4.86$468,290.16View SEC Filing  
1/15/2014Wilfred JaegerDirectorSell424,956$4.87$2,069,535.72View SEC Filing  
1/10/2014Wilfred JaegerDirectorSell723,900$4.88$3,532,632.00View SEC Filing  
7/15/2013Wilfred E JaegerDirectorSell322,000$5.53$1,780,660.00View SEC Filing  
7/11/2013Wilfred E JaegerDirectorSell178,000$5.51$980,780.00View SEC Filing  
7/5/2013Wilfred E JaegerDirectorSell219,667$5.53$1,214,758.51View SEC Filing  
6/19/2013Wilfred E JaegerDirectorSell2,000$5.50$11,000.00View SEC Filing  
6/18/2013Wilfred E JaegerDirectorSell124,733$5.51$687,278.83View SEC Filing  
6/10/2013Wilfred E JaegerDirectorSell153,600$5.48$841,728.00View SEC Filing  
5/31/2013David L AndersonMajor ShareholderSell266,542$5.72$1,524,620.24View SEC Filing  
5/31/2013Jeffrey W BirdDirectorSell273,181$5.72$1,562,595.32View SEC Filing  
5/22/2013Tillman PearceInsiderSell20,000$5.63$112,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Threshold Pharmaceuticals (NASDAQ:MTEM)
Latest Headlines for Threshold Pharmaceuticals (NASDAQ:MTEM)
DateHeadline logoThreshold Pharmaceuticals, Inc. (MTEM) Stock Rating Lowered by Zacks Investment Research - September 17 at 12:56 PM logoMolecular Templates to Present at the BioCentury 24th Annual Newsmakers in the Biotech Industry Conference - September 7 at 6:26 AM logoThreshold Pharmaceuticals, Inc. (MTEM) Downgraded by ValuEngine to Strong Sell - September 2 at 9:26 PM logoMolecular Templates to Ring NASDAQ Closing Bell Friday, September 1, 2017 - August 31 at 7:30 AM logoHead to Head Survey: Corvus Pharmaceuticals (CRVS) vs. Threshold Pharmaceuticals (MTEM) - August 23 at 4:26 AM logoAustin biotech company lands on Nasdaq with fresh $60 million - August 17 at 5:27 AM logo Brokerages Anticipate Threshold Pharmaceuticals, Inc. (MTEM) Will Announce Earnings of -$0.33 Per Share - August 16 at 2:14 PM logoMolecular Templates to Present at the 2017 Wedbush PacGrow Healthcare Conference - August 15 at 2:22 AM logoMolecular Templates Potential Catalysts, Merger Synergies and Pipeline Review - August 11 at 6:42 AM logoTakeda and Molecular Templates Announce Multi-Target Research and Licensing Collaboration to Develop Next-Generation Oncology Therapies - August 4 at 5:48 AM logoMolecular Templates Completes Merger with Threshold Pharmaceuticals and Private Placements - August 4 at 5:48 AM logoBenzinga's Top Upgrades, Downgrades For August 3, 2017 - Benzinga - August 3 at 12:52 PM logoTakeda and Molecular Templates Announce Multi-Target Research and Licensing Collaboration to Develop Next ... - Business Wire (press release) - August 3 at 12:52 PM logo5.87 - MarketWatch - August 3 at 12:52 PM



Threshold Pharmaceuticals (MTEM) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff